FY2018 EPS Estimates for Amneal Pharmaceuticals Inc Reduced by SunTrust Banks (AMRX)

Amneal Pharmaceuticals Inc (NYSE:AMRX) – Research analysts at SunTrust Banks decreased their FY2018 EPS estimates for shares of Amneal Pharmaceuticals in a research note issued on Monday, October 15th. SunTrust Banks analyst J. Boris now anticipates that the company will earn $0.94 per share for the year, down from their previous estimate of $0.98. SunTrust Banks currently has a “Hold” rating and a $15.00 target price on the stock. SunTrust Banks also issued estimates for Amneal Pharmaceuticals’ Q4 2018 earnings at $0.30 EPS, FY2019 earnings at $1.24 EPS and FY2020 earnings at $1.66 EPS.

Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings results on Thursday, August 9th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. Amneal Pharmaceuticals had a negative net margin of 52.94% and a negative return on equity of 8.74%. The firm had revenue of $462.33 million during the quarter, compared to the consensus estimate of $460.82 million. The business’s revenue for the quarter was down 2.5% on a year-over-year basis.

A number of other research firms also recently commented on AMRX. Cantor Fitzgerald reiterated a “buy” rating and issued a $35.00 price objective on shares of Amneal Pharmaceuticals in a report on Thursday, August 9th. Canaccord Genuity reiterated a “hold” rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a report on Tuesday, September 4th. Zacks Investment Research upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a report on Saturday, July 14th. BMO Capital Markets increased their price objective on shares of Amneal Pharmaceuticals from $19.00 to $20.00 and gave the company a “market perform” rating in a report on Friday, August 10th. Finally, ValuEngine downgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 27th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $22.75.

AMRX stock opened at $18.47 on Wednesday. The stock has a market capitalization of $6.62 billion, a price-to-earnings ratio of 29.37, a price-to-earnings-growth ratio of 0.98 and a beta of 1.41. The company has a debt-to-equity ratio of 2.85, a current ratio of 2.01 and a quick ratio of 1.25. Amneal Pharmaceuticals has a 12 month low of $13.47 and a 12 month high of $24.48.

In other news, SVP Nikita Shah sold 50,000 shares of the stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $23.46, for a total value of $1,173,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Bryan M. Reasons sold 11,698 shares of the stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $23.65, for a total transaction of $276,657.70. The disclosure for this sale can be found here. 3.20% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. Fosun International Ltd purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at approximately $333,013,000. FMR LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at approximately $130,351,000. BlackRock Inc. purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at approximately $95,312,000. TPG Group Holdings SBS Advisors Inc. purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at approximately $67,438,000. Finally, TCW Group Inc. purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at approximately $42,390,000. 32.41% of the stock is owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.

Featured Story: Intrinsic Value

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply